Novartis Offers Mixed Earnings Report As It Approaches A Key SpinoffInvestors Business Daily • 10/25/22
Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful superiority over anti-C5 treatment in Phase III APPLY-PNH studyGlobeNewsWire • 10/24/22
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancerGlobeNewsWire • 10/14/22
Novartis outlines plan to become a 'top-five player' in U.S. pharmaceuticals marketMarket Watch • 09/23/22
Novartis unveils new focused strategy, underpinned by eight potential multi-billion dollar peak sales brands & deep pipeline, at Meet the Management eventGlobeNewsWire • 09/22/22